<p>礼来（NYSE: LLY）股票最近一直是投资者的赢家，这在很大程度上归功于对肥胖药物的强劲消费需求。截至目前，股价已经飙升了近 60%，同时投资者还获得了每股 1.30 美元的季度股息，年度股息率为 0.56%。2023 年年底，管理层宣布将季度分红金额提高了 15%，并自那时起一直保持稳定。</p>
<p>尽管礼来股票已经接近 52 周高点，但华尔街分析师认为股价刚刚起步，可能将飙升至天际。如果他们是对的，礼来可能会成为 2024 年加入股票分拆俱乐部的下一家公司，从而将代表性扩展到技术领域之外，已经在制药领域取得成功的英伟达（Nasdaq: NVDA）和博通（Nasdaq: AVGO）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/03/imageForEntry17-Zay.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/03/imageForEntry17-Zay.jpg"/></p>
<h2>华尔街看涨</h2>
<p>贝伦贝格：贝伦贝格分析师凯瑞·霍尔福德首次将礼来股票的目标价上调了 17.6%，从 850 美元提高到 1,000 美元，并维持买入评级。新的目标价表明，礼来股票在短期内还有 8% 的上涨空间。或许更重要的是，贝伦贝格分析师相信礼来股票将突破心理上敏感的 1,000 美元门槛，这可能会引发关于潜在股票分拆的进一步热议。</p>
<p>摩根大通：华尔街公司摩根大通同样认为，礼来股票的交易价值应该达到 1,000 美元，将目标价从 900 美元提高到该水平，并在公司 2024 年第二季度财报公布前给予超配评级。摩根大通分析师表示，减肥药物价格值得讨论，但他们认为还有长期上涨潜力有待发挥。</p>
<h2>2024 年礼来股票会分拆吗？</h2>
<p>如果礼来的董事会决定在 2024 年进行股票分拆，这将不是第一次。该公司在其历史上进行过几次股票分拆，每次比例为 2:1，但都不在 21 世纪。上一次礼来进行股票分拆是在 1997 年，当时股价约为 100 美元。现在股价正迅速上涨至 1,000 美元，而华尔街分析师认为股价有望在短期内达到这一水平，礼来管理层可能正在认真考虑重新审视他们的股票分拆策略。</p>
<p>尤其是考虑到公司强劲的基本面，包括不断增长的营收。去年，礼来的营收超过 340 亿美元，较 2022 年增长 19%。其营收增长的很大一部分来自于其肥胖药物 Zepbound 和 Mounjaro 的销售。2024 年第一季度，Mounjaro 的销售额大约翻了一番，达到 18.1 亿美元，而 Zepbound 的营收在该季度达到 5.174 亿美元。礼来还专注通过一系列收购来实现其药物组合的多样化。</p>
<p>礼来将其 2024 年总营收展望提高 20 亿美元，至 424 亿美元至 436 亿美元的范围，这归功于其减肥药物的强劲表现。随着这种增长和需求预测，礼来的股价可能会继续反映这种看涨势头，有可能达到 1,000 美元每股，作为对此的回应，潜在的股票分拆可能会成为可能。</p>
<h2><strong>警报：立即参加这个退休问卷（赞助）</strong></h2>
<p>立即参加以下问卷，今天就与一位理财顾问匹配。</p>
<p>每位顾问都经过 SmartAsset 的审核，并被要求遵守以您的最佳利益行事的受托人标准。</p>
<p>操作步骤如下：</p>
<ol>
<li>
<p>回答 SmartAsset 顾问匹配问卷</p>
</li>
<li>
<p>在您方便的时候查看您的预先筛选匹配项。查看顾问的个人资料。</p>
</li>
<li>
<p>与顾问免费交谈。通过电话进行介绍性通话或亲自介绍，并选择未来要与之合作的人</p>
</li>
</ol>
<p>立即参加退休问卷。</p>
<p>本文来源：24/7 Wall St..</p>

礼来

<p>礼来（Eli Lilly）的股票因消费者对肥胖药物的强劲需求而出现了显著增长。华尔街分析师预测，该股票可能会继续上涨，有望达到每股 1000 美元。如果这种情况发生，有人猜测礼来可能会考虑在 2024 年进行股票分拆。该公司有进行股票分拆的历史，上一次分拆是在 1997 年。凭借强劲的营收增长和专注于多样化其药物组合，预计礼来的股价将反映这种看涨势头</p>

<p>Eli Lilly (NYSE: LLY) stock has been a winner for investors of late, owing largely to strong consumer demand for obesity drugs. Shares have ballooned by nearly 60% year-to-date, while investors have also collected a quarterly dividend of $1.30 per share for an annual dividend yield of 0.56%. At year-end 2023, management announced a 15% increase to the quarterly distribution amount and has held it steady ever since.</p>
<div class="lb-trans"><p>礼来（NYSE: LLY）股票最近一直是投资者的赢家，这在很大程度上归功于对肥胖药物的强劲消费需求。截至目前，股价已经飙升了近 60%，同时投资者还获得了每股 1.30 美元的季度股息，年度股息率为 0.56%。2023 年年底，管理层宣布将季度分红金额提高了 15%，并自那时起一直保持稳定。</p>
</div><p>While LLY stock is already trading within grasp of its 52-week high, Wall Street analysts believe shares are just getting started and could be headed for the stratosphere. If they’re right, Eli Lilly could be the next company to join the stock-split club in 2024, thereby expanding representation beyond the technology sector, where Nvidia (Nasdaq: NVDA) and Broadcom (Nasdaq: AVGO) have already made a splash, into pharma.</p>
<div class="lb-trans"><p>尽管礼来股票已经接近 52 周高点，但华尔街分析师认为股价刚刚起步，可能将飙升至天际。如果他们是对的，礼来可能会成为 2024 年加入股票分拆俱乐部的下一家公司，从而将代表性扩展到技术领域之外，已经在制药领域取得成功的英伟达（Nasdaq: NVDA）和博通（Nasdaq: AVGO）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/03/imageForEntry17-Zay.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/03/imageForEntry17-Zay.jpg"/></p>
<h2>Wall Street Bulls</h2>
<div class="lb-trans"><h2>华尔街看涨</h2>
</div><p>Berenberg: Out of the gate, Berenberg analyst Kerry Holford lifted the firm’s price target on Eli Lilly stock by 17.6% to $1,000 from $850 and maintained a buy rating. The new price target suggests LLY stock has runway for another 8% upside in the near term. Perhaps more importantly the Berenberg analyst is confident that Eli Lilly stock will cross the psychologically sensitive $1,000 threshold, which is likely to ignite further buzz about a potential stock split.</p>
<div class="lb-trans"><p>贝伦贝格：贝伦贝格分析师凯瑞·霍尔福德首次将礼来股票的目标价上调了 17.6%，从 850 美元提高到 1,000 美元，并维持买入评级。新的目标价表明，礼来股票在短期内还有 8% 的上涨空间。或许更重要的是，贝伦贝格分析师相信礼来股票将突破心理上敏感的 1,000 美元门槛，这可能会引发关于潜在股票分拆的进一步热议。</p>
</div><p>JPMorgan: Wall Street firm JPMorgan similarly believes Eli Lilly stock should be trading at $1,000, lifting the price target from $900 to that level with an overweight rating leading up to the company’s Q2 earnings report in August. JPMorgan analysts say weigh loss drug prices are worthy of debate but believe there is long-term upside potential yet to play out.</p>
<div class="lb-trans"><p>摩根大通：华尔街公司摩根大通同样认为，礼来股票的交易价值应该达到 1,000 美元，将目标价从 900 美元提高到该水平，并在公司 2024 年第二季度财报公布前给予超配评级。摩根大通分析师表示，减肥药物价格值得讨论，但他们认为还有长期上涨潜力有待发挥。</p>
</div><h2>Will There Be an Eli Lilly Stock Split in 2024?</h2>
<div class="lb-trans"><h2>2024 年礼来股票会分拆吗？</h2>
</div><p>If Eli Lilly’s board of directors decided to complete a stock split in 2024, it wouldn’t be the first time. The company has a handful of stock splits in its history, each of which had a 2:1 ratio, but none of them have been in the 21st century. The last time that Eli Lilly split its shares was in 1997, when the stock was hovering at approximately $100 per share. Now that shares are barreling toward $1,000, and Wall Street analysts believe it has a shot at this level in the near term, Eli Lilly management might seriously be considering revisiting their share-split strategy.</p>
<div class="lb-trans"><p>如果礼来的董事会决定在 2024 年进行股票分拆，这将不是第一次。该公司在其历史上进行过几次股票分拆，每次比例为 2:1，但都不在 21 世纪。上一次礼来进行股票分拆是在 1997 年，当时股价约为 100 美元。现在股价正迅速上涨至 1,000 美元，而华尔街分析师认为股价有望在短期内达到这一水平，礼来管理层可能正在认真考虑重新审视他们的股票分拆策略。</p>
</div><p>This is especially true given the company’s strong fundamentals, including revenue that is growing hand over fist. Last year, Eli Lilly generated a whopping $34 billion-plus in revenue, a 19% increase over 2022 levels. Much of its revenue growth is being fueled by sales for its obesity drugs, Zepbound and Mounjaro. In Q1 2024, sales of Mounjaro roughly doubled to $1.81 billion amid rising prices and soaring demand. Zepbound revenue hovered at $517.4 million in the quarter. Eli Lilly is also focused on diversifying its drug portfolio through a series of acquisitions.</p>
<div class="lb-trans"><p>尤其是考虑到公司强劲的基本面，包括不断增长的营收。去年，礼来的营收超过 340 亿美元，较 2022 年增长 19%。其营收增长的很大一部分来自于其肥胖药物 Zepbound 和 Mounjaro 的销售。2024 年第一季度，Mounjaro 的销售额大约翻了一番，达到 18.1 亿美元，而 Zepbound 的营收在该季度达到 5.174 亿美元。礼来还专注通过一系列收购来实现其药物组合的多样化。</p>
</div><p>Eli Lilly increased its 2024 total revenue outlook by $2 billion to a range of $42.4 billion-$43.6 billion, owing to strong performance from its weight loss drugs. With this type of growth and demand in the forecast, Eli Lilly’s stock price is likely to continue to reflect this bullish momentum, potentially to $1,000 per share, in response to which a potential stock split could be in the cards.</p>
<div class="lb-trans"><p>礼来将其 2024 年总营收展望提高 20 亿美元，至 424 亿美元至 436 亿美元的范围，这归功于其减肥药物的强劲表现。随着这种增长和需求预测，礼来的股价可能会继续反映这种看涨势头，有可能达到 1,000 美元每股，作为对此的回应，潜在的股票分拆可能会成为可能。</p>
</div><h2><strong>ALERT: Take This Retirement Quiz Now (Sponsored)</strong></h2>
<div class="lb-trans"><h2><strong>警报：立即参加这个退休问卷（赞助）</strong></h2>
</div><p>Take the quiz below to get matched with a financial advisor today.</p>
<div class="lb-trans"><p>立即参加以下问卷，今天就与一位理财顾问匹配。</p>
</div><p>Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.</p>
<div class="lb-trans"><p>每位顾问都经过 SmartAsset 的审核，并被要求遵守以您的最佳利益行事的受托人标准。</p>
</div><p>Here’s how it works:</p>
<p>1. Answer SmartAsset advisor match quiz</p>
<p>2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.</p>
<p>3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future</p>
<div class="lb-trans"><p>操作步骤如下：</p>
<ol>
<li>
<p>回答 SmartAsset 顾问匹配问卷</p>
</li>
<li>
<p>在您方便的时候查看您的预先筛选匹配项。查看顾问的个人资料。</p>
</li>
<li>
<p>与顾问免费交谈。通过电话进行介绍性通话或亲自介绍，并选择未来要与之合作的人</p>
</li>
</ol>
</div><p>Take the retirement quiz right here.</p>
<div class="lb-trans"><p>立即参加退休问卷。</p>
</div><p>The post Will Wall Street Darling Eli Lilly’s Stock Split Next? appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>本文来源：24/7 Wall St..</p>
</div>

华尔街宠儿礼来的股票会进行拆股吗？